Selective Janus kinase inhibitors come of age

被引：59
作者：
O'Shea, John J. [1 ]
Gadina, Massimo [2 ]
机构：
[1] NIAMSD, Mol Immunol & Inflammat Branch, Bethesda, MD 20892 USA
[2] NIAMSD, Translat Immunol Sect, Bethesda, MD 20892 USA
来源：
NATURE REVIEWS RHEUMATOLOGY | 2019年 / 15卷 / 02期
关键词：
D O I：
10.1038/s41584-018-0155-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Janus kinase (JAK) inhibitors (jakinibs) that target downstream signalling by a large range of cytokines are effective in treating autoimmune and rheumatic diseases. Newer jakinibs that selectively inhibit individual JAKs and a narrower spectrum of cytokines have now been developed, but how do these inhibitors compare with existing drugs?
引用
收藏
页码：74 / 75
页数：3
相关论文
共 9 条
  • [1] A Case Series on Patients on Tofacitinib in Combination With a Biologic
    Barroso, Nashla S.
    Miller, Elizabeth Z.
    Furst, Daniel E.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 (06) : 349 - 351
  • [2] Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
    Burmester, Gerd R.
    Kremer, Joel M.
    Van den Bosch, Filip
    Kivitz, Alan
    Bessette, Louis
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Pangan, Aileen L.
    Camp, Heidi S.
    [J]. LANCET, 2018, 391 (10139) : 2503 - 2512
  • [3] Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
    Dengler, Hart S.
    Wu, Xiumin
    Peng, Ivan
    Rinderknecht, Cornelia H.
    Kwon, Youngsu
    Suto, Eric
    Kohli, Pawan Bir
    Liimatta, Marya
    Barrett, Kathy
    Lloyd, Julia
    Cain, Gary
    Briggs, Mike
    Addo, Stephanie
    Salmon, Gary
    Ubhayakar, Savita
    Deshmukh, Gauri
    Shahidi-Latham, Sheerin K.
    Quiason-Huynh, Cristine M.
    Jackman, Janet
    Liu, John
    Ray, Nicholas C.
    Goodacre, Simon C.
    Johnson, Adam
    McKenzie, Brent S.
    Lee, Wyne P.
    Zak, Mark
    Kenny, Jane R.
    Ghilardi, Nico
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (468)
  • [4] Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
    Gadina, Massimo
    Johnson, Catrina
    Schwartz, Daniella
    Bonelli, Michael
    Hasni, Sarfaraz
    Kanno, Yuka
    Changelian, Paul
    Laurence, Arian
    O'Shea, John J.
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2018, 104 (03) : 499 - 514
  • [5] Genovese M. C., LANCET
  • [6] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
    Mease, Philip
    Coates, Laura C.
    Helliwell, Philip S.
    Stanislavchuk, Mykola
    Rychlewska-Hanczewska, Anna
    Dudek, Anna
    Abi-Saab, Walid
    Tasset, Chantal
    Meuleners, Luc
    Harrison, Pille
    Besuyen, Robin
    Van der Aa, Annegret
    Mozaffarian, Neelufar
    Greer, Joy M.
    Kunder, Rebecca
    Van den Bosch, Filip
    Gladman, Dafna D.
    [J]. LANCET, 2018, 392 (10162) : 2367 - 2377
  • [7] Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
    Papp, Kim
    Gordon, Kenneth
    Thaci, Diamant
    Morita, Akimichi
    Gooderham, Melinda
    Foley, Peter
    Girgis, Ihab G.
    Kundu, Sudeep
    Banerjee, Subhashis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14) : 1313 - 1321
  • [8] van der Heijde D., LANCET, V392
  • [9] The emerging safety profile of JAK inhibitors in rheumatic disease
    Winthrop, Kevin L.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2017, 13 (04) : 234 - 243
1